[Methodology and aims of the European Cubicin® Outcome Registry and Experience (EUCORE) database]

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Health Services Research

Context:

• Phase III randomized controlled trials (RCTs) for antimicrobials primarily aim for regulatory approval.
• These RCTs often include low-risk patients, limiting generalizability to real-world infections, especially those involving antibiotic-resistant bacteria.
• The controlled environment of RCTs may not reflect actual clinical practice, necessitating complementary study designs.

Purpose:

• To evaluate the utility of post-authorization studies as a complement to traditional clinical trials for antimicrobials.
• To analyze data from the EUCORE registry, a European multicenter, retrospective, non-comparative study of daptomycin use.
• To highlight the importance of interpreting real-world data from observational studies despite their inherent limitations.

Summary:

• The EUCORE registry collected data on patients receiving daptomycin, offering real-world insights post-commercialization.
• This retrospective, non-comparative study complements findings from phase III trials by examining antibiotic use in a broader patient population.
• The study underscores the value of analyzing observational data to understand antimicrobial effectiveness and challenges in clinical practice.

Impact:

• Provides valuable real-world data on daptomycin use, supplementing evidence from controlled trials.
• Informs clinical decision-making and antibiotic stewardship by offering insights into actual treatment outcomes.
• Highlights the necessity of robust post-authorization surveillance for understanding the long-term clinical utility of new antimicrobial agents.